secwatch.observer — SEC 8-K summary
======================================

Issuer:     ACHIEVE LIFE SCIENCES, INC. (ACHV)
CIK:        0000949858
Form:       8-K
Filed at:   2023-08-14T23:59:59+00:00
Accession:  0000950170-23-042382
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Achieve Life Sciences Q2 net loss $8.2M, cash $25.1M; advances cytisinicline NDA submission H1 2024
--------------------------------------------------------------------------------

- Net loss of $8.2M in Q2 2023; cash, equivalents and restricted cash $25.1M as of June 30, 2023.
- Positive Phase 3 ORCA-3 trial confirmed cytisinicline efficacy/safety for smoking cessation in 792 smokers.
- Phase 2 ORCA-V1: cytisinicline increased odds of quitting vaping 2.6x vs placebo (31.8% vs 15.1%).
- Plan to submit New Drug Application for cytisinicline in first half of 2024.
- Raised $16.5M in registered direct offering; refinanced $16.6M SVB debt with maturity to Dec 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/949858/000095017023042382/0000950170-23-042382-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/949858/000095017023042382/achv-20230814.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-042382

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer